These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8308312)

  • 21. Post-kala-azar dermal leishmaniasis.
    Baghestani S; Handjani F; Sodeifi M; Kumar PV
    Eur J Dermatol; 1998 Jun; 8(4):277-9. PubMed ID: 9649686
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An unusual presentation of post-kala-azar dermal leishmaniasis.
    Ramesh V; Kumar J; Salotra P
    Trop Doct; 2007 Jul; 37(3):172-3. PubMed ID: 17716510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in age incidence of kala-azar in India.
    Basu D; Mallik KK
    Indian J Public Health; 1995; 39(1):26. PubMed ID: 8690477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of leishmanin skin test antigen sensitivity and potency in a longitudinal study of visceral leishmaniasis in Bangladesh.
    Bern C; Amann J; Haque R; Chowdhury R; Ali M; Kurkjian KM; Vaz L; Wagatsuma Y; Breiman RF; Secor WE; Maguire JH
    Am J Trop Med Hyg; 2006 Oct; 75(4):744-8. PubMed ID: 17038705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum citrulline is a simple quantitative marker for small intestinal enterocytes mass and absorption function in short bowel patients.
    Jianfeng G; Weiming Z; Ning L; Fangnan L; Li T; Nan L; Jieshou L
    J Surg Res; 2005 Aug; 127(2):177-82. PubMed ID: 15921697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of visceral leishmaniasis associated with the behaviors of the people in rural areas.
    Shah H
    JNMA J Nepal Med Assoc; 2005; 44(160):116-20. PubMed ID: 16751812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deaths in visceral leishmaniasis (Kala-azar) during treatment.
    Ahasan HA; Chowdhury MA; Azhar MA; Rafiqueuddin AK; Azad KA
    Med J Malaysia; 1996 Mar; 51(1):29-32. PubMed ID: 10967976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outbreak of kala-azar in Bombay.
    Bhatia S; Patel N; Gulhane S; Dongre V; Jijina FF; Pathare AV
    J Postgrad Med; 1995; 41(1):3-4. PubMed ID: 10740690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of rK39 for diagnosis of post kala-azar dermal leishmaniasis in Nepal.
    Das ML; Deb M; Karki BM; Sarif M; Khanal B; Bhattacharya SK; Agrawal S; Koirala S
    Southeast Asian J Trop Med Public Health; 2007 Jul; 38(4):619-25. PubMed ID: 17882997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiological, clinical and therapeutic features of pediatric kala-azar.
    Rahim KM; Ashkan MM
    Southeast Asian J Trop Med Public Health; 2007 Jul; 38(4):626-30. PubMed ID: 17882998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kala-azar epidemic in Varanasi district, India.
    Kumar R; Kumar P; Chowdhary RK; Pai K; Mishra CP; Kumar K; Pandey HP; Singh VP; Sundar S
    Bull World Health Organ; 1999; 77(5):371-4. PubMed ID: 10361752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.
    de la Rosa R; Pineda JA; Delgado J; Macías J; Morillas F; Martín-Sánchez J; Leal M; Sánchez-Quijano A; Lissen E
    Clin Infect Dis; 2001 Feb; 32(4):633-5. PubMed ID: 11181128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diagnostic value of the d-xylose test in young children].
    Chantraine JM; Steveler MC
    Acta Paediatr Belg; 1967; 21(1):91-103. PubMed ID: 6044264
    [No Abstract]   [Full Text] [Related]  

  • 35. Recent observations on the epidemiology of kala-azar in the eastern and central states of the Sudan.
    el-Hassan AM; Zijlstra EE; Ismael A; Ghalib HW
    Trop Geogr Med; 1995; 47(4):151-6. PubMed ID: 8560585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post kala-azar dermal leishmaniasis (PKDL): a first case report from Nepal.
    Karki P; Koirala S; Parija SC; Sethi M; Das ML
    Indian J Pathol Microbiol; 2003 Apr; 46(2):214-5. PubMed ID: 15022913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A thirty day course of sodium stibogluconate for treatment of Kala-azar in Nepal.
    Karki P; Koirala S; Parija SC; Hansdak SG; Das ML
    Southeast Asian J Trop Med Public Health; 1998 Mar; 29(1):154-8. PubMed ID: 9740292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 1H NMR spectroscopic method for diagnosis of malabsorption syndrome: a pilot study.
    Bala L; Nagana Gowda GA; Ghoshal UC; Misra A; Bhandari M; Khetrapal CL
    NMR Biomed; 2004 Apr; 17(2):69-75. PubMed ID: 15052554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Demonstration of Leishmania parasites in skin lesions of Indian post kala-azar dermal leishmaniasis (PKDL) cases.
    Sharma MC; Gupta AK; Verma N; Das VN; Saran R; Kar SK
    J Commun Dis; 2000 Mar; 32(1):67-8. PubMed ID: 11129569
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.
    Ismail A; El Hassan AM; Kemp K; Gasim S; Kadaru AE; Moller T; Kharazmi A; Theander TG
    J Pathol; 1999 Dec; 189(4):615-22. PubMed ID: 10629566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.